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Anxiety sensitivity, its stability 
and longitudinal association with 
severity of anxiety symptoms
Johanna H. M. Hovenkamp-Hermelink  1, Date C. van der Veen1, Richard C. oude Voshaar1, 
Neeltje M. Batelaan2,3, Brenda W.J.H. penninx2,3, Bertus F. Jeronimus1,4, Robert A. schoevers1 
& Harriëtte Riese1
Anxiety sensitivity is associated with the onset of panic attacks, anxiety, and other common mental 
disorders. Anxiety sensitivity is usually seen as a relative stable trait. However, previous studies were 
inconclusive regarding the longitudinal stability of anxiety sensitivity and differed in study designs 
and outcomes. the current study examines the stability of anxiety sensitivity over time and its 
longitudinal associations with severity of anxiety symptoms. participants from the Netherlands study 
of Depression and Anxiety with and without an anxiety, depressive, or comorbid anxiety-depressive 
disorder diagnosis were included (N = 2052). Stability in anxiety sensitivity over two year follow-up 
and the longitudinal association between the change in anxiety sensitivity and change in severity of 
anxiety symptoms were tested. Results indicated that two-year stability of anxiety sensitivity was high 
(r = 0.72), yet this test-retest estimate leaves room for changes in anxiety sensitivity in some individuals 
as well. Change in anxiety sensitivity was positively associated with change in severity of anxiety 
symptoms (B = 0.64 in univariable analysis and B = 0.52 in multivariable analysis). The longitudinal 
association of anxiety sensitivity with severity of anxiety symptoms indicates that targeting anxiety 
sensitivity may be of additional benefit in clinical practice.
Anxiety sensitivity (AS) is a psychological risk factor that has received a lot of attention in clinical and epide-
miological studies of anxiety disorders. AS can be described as the ‘fear of fear’ or the fear of anxiety-related 
symptoms such as heart palpitations, sweating, or shaking, due to the belief that these symptoms have negative 
consequences1. There is a lot of literature indicating that elevated AS levels predict the onset of anxiety symptoms 
and panic attacks2,3 as well as Axis I diagnoses, particularly anxiety and depressive disorders4,5. Furthermore, AS 
was found to be predictive of persistence of anxiety disorders in a four-year follow-up study in an earlier study in 
our sample6. Despite these findings, it remains unclear whether AS is also associated with the severity of anxiety 
symptoms over time, which is important, because higher severity of anxiety symptoms is associated with a poorer 
prognosis of anxiety and depressive disorder trajectories7,8.
Another question concerns the temporal stability of AS, which relates to the discussion whether AS can be 
distinguished from trait anxiety. Some scholars postulated that AS and trait anxiety are closely related and cannot 
be clearly distinguished from each other9,10. Others argue that AS and trait anxiety, although related, are different 
entities11–14 and called AS a ‘trait-like’ construct. If AS is akin to trait-anxiety AS should be equally stable over 
time. However, previous studies addressing the issue of AS stability over time were inconsistent. Reasonable AS 
stability was observed over a 44-week period (r = 0.72) in a study of 86 outpatients with one or more anxiety dis-
orders15. Another study of 1277 high school students with four yearly assessments identified three subgroups with 
different AS stability trajectories16: A group with stable low (n = 1277), a group with stable high (n = 140) AS lev-
els, and a groups with AS levels that increased over time (n = 320). Comparable results with three classes, that is 
normative-stable, high-stable, and high-unstable trajectories of AS, were reported by Allan et al.17. In addition, in 
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an adolescents population a normative developmental change in AS was found over an on average two-year time 
period with a correlation of 0.4718. These longitudinal studies suggests that in some individuals AS can change 
substantially, a perspective that is in line with the results of a study in 1296 young adults attending intensive mil-
itary training. In this healthy sample, AS was found to increase within five weeks in response to stressful physical 
and mental events that triggered anxiety symptoms and panic attacks19. Contrarily, reductions in AS within eight 
weeks to six months have been observed in response to cognitive behavior treatment and pharmacotherapy20–24. 
This literature indicates that in adults AS can change rapidly in highly stressful or treatment conditions, but little 
is known about the persistence of such changes over time. Moreover, the literature that describes AS as akin to 
trait anxiety would suggest that AS is relatively stable in the absence of perturbations. Hitherto, the literature lacks 
an estimate of AS stability over more than twelve months in healthy adults and those with mood symptoms, and 
this paper was aimed to fill this gap.
In the current study we aim to test the two-year stability of AS and analyze whether a longitudinal association 
exists between a change in AS and change in severity of anxiety symptoms. As the values of AS and severity of 
anxiety symptoms measured at consecutive time points are correlated, statistical analysis of longitudinal asso-
ciations should account for dependencies between these data and adjust for within-subject correlations. This 
paper is the first to apply such methods to this question. Using generalized estimating equations (GEE) analysis, 
our models were fit in a heterogeneous sample of participants with a diagnosed anxiety disorder, a depressive 
disorder, or comorbid anxiety-depressive disorder, as well as participants with no current or lifetime history of an 
anxiety or depressive disorder. By doing so, the current study extends the previous studies on AS by using a large 
and heterogeneous sample of participants from various settings and stages of psychopathology. The objectives of 
the current study are to examine: i) the stability of AS over a two-year time period; ii) whether a change in AS is 
associated with a concurrent change in severity of anxiety symptoms.
Materials and Methods
study sample. The Netherlands Study of Depression and Anxiety (NESDA) is a national study designed to 
investigate the course and consequences of depressive and anxiety disorders. At baseline the study included 2981 
participants with a mean age of 41.86 years (SD = 13.08, range 18–65 years; 66.39% women), including partic-
ipants with a past or current depressive and/or anxiety disorder diagnosis (n = 2329; 78.12%) and participants 
without such a diagnosis (n = 652; 21.87%). To represent various settings and stages of psychopathology, partic-
ipants were recruited in the general population (n = 564; 18.91%), in general practices (n = 1610; 54.01%), and 
in mental health organizations (n = 807; 27.07%). Excluded were participants with a primary psychotic, obses-
sive-compulsive, bipolar or severe addiction disorder and those not being fluent in Dutch. More details of the 
NESDA study, its design and attrition rates have been described elsewhere25,26. For the current study, NESDA data 
from baseline and the two-year follow-up were used. The investigation was carried out in accordance with the 
Declaration of Helsinki. The research protocol was approved by the Medical Ethics Review Board (METc) of the 
VU University Medical Centre Amsterdam27, the Medical Ethics Review Board (METc) of the University Medical 
Center Groningen28, and the Medical Ethics Review Board (METc) of the Leiden University Medical Center29, 
and subsequently by local review boards of each participating center. Written informed consent was obtained 
from all respondents.
procedure. At baseline and at two-year follow-up, 1-month diagnoses of anxiety (social anxiety disorder, 
panic disorder with and without agoraphobia, agoraphobia, and generalized anxiety disorder) and depressive dis-
orders (dysthymia and major depressive disorder) were established with the highly reliable and valid Composite 
International Diagnostic Interview (CIDI, version 2.1) based on the DSM-IV30. The interviews were conducted by 
a specially trained clinical research staff. The research assistants, who performed the CIDI interviews at follow-up, 
were blind for baseline diagnoses.
As anxiety symptoms are not limited to anxiety disorders, but are also common in other affective disorders, 
including depression7 and individuals without an affective disorder diagnosis31 we included participants with an 
anxiety disorder diagnosis (at least one current anxiety disorder), a unipolar depressive disorder diagnosis, or a 
comorbid anxiety-depressive disorder diagnosis, as well as participants without a current or lifetime anxiety or 
depressive disorder. Excluded were participants who had neither AS nor severity of anxiety symptoms data at 
both baseline and two-year follow-up (n = 10), resulting in a sample of N = 2052 available for statistical analysis.
self-report questionnaires. Anxiety sensitivity. At baseline and at two-year follow-up AS levels were 
assessed with the Anxiety Sensitivity Index (ASI). The ASI is a self-report questionnaire, consisting of 16 items. 
The ASI quantifies the fear of anxiety-related symptoms and the concerns about negative consequences of anxiety 
symptoms32. Participants were asked to what extent the items applied to them at the time of measuring. The ASI 
uses a 5-point Likert scale, ranging from 1 (very little) to 5 (very much). The ASI is scored by summing the ratings 
for all of the 16 items to obtain a total score that can range from 16 to 80, and can be used as one dimension33. The 
ASI has high internal consistency, adequate test-retest reliability, and good validity32,34. Participants with a miss-
ing observation at one of the assessment waves were included in the analyses (baseline n = 469, 22.86%; two-year 
follow-up n = 498, 24.27%), as the planned statistical analysis can adequately handle missing data.
Severity of anxiety symptoms. Severity of anxiety symptoms (further referred to as anxiety severity) was deter-
mined using the Beck Anxiety Inventory (BAI). The BAI is a self-report instrument with 21 items that assesses 
the overall severity of anxiety symptoms over the past week on a 4-point Likert scale, ranging from 0 (not at all) 
to 3 (severely, I could barely stand it). The BAI has shown to have high internal consistency, and good test-retest 
reliability35. The total BAI sum score ranges from 0 to 63. Participants with a missing observation at one of the 
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assessment waves were included in the analyses (baseline n = 11, 0.54%; two-year follow-up n = 348, 16.96%), as 
the planned statistical analysis can adequately handle missing data.
Covariates. Years of education was included as time-independent covariates36. This also applied to age and gen-
der37,38. Also the reported duration of anxiety symptoms at baseline was included, since this associates with a more 
severe and chronic course of anxiety and depressive disorders38,39. Duration of anxiety symptoms corresponds to 
the number of months with anxiety symptoms of at least mild severity in the four years prior to baseline, assessed 
with Life Chart Interview (LCI). The LCI is a standardized interview to retrospectively determine the presence and 
severity of anxiety and avoidance symptoms40. Finally, to account for possible treatment effects, the time-dependent 
covariates receiving psychological treatment in the last six months before assessment (yes or no, based on Trimbos/
iMTA questionnaire for Costs associated with Psychiatric Illness (TIC-P)41, and use of antidepressants (50% of the 
days of a month or more often; yes or no) were included.
Data analysis. Descriptive statistics were used to present the baseline characteristics of the study sample. 
Asmundson et al.33 evaluated the structure of the ASI and found evidence that the latent structure of anxiety 
sensitivity is dimensional. Therefore, the ASI was used as a continuous measure. Distributions of AS and anxiety 
severity were checked and found to deviate from a normal distribution.
The changes of AS and anxiety severity scores from baseline to two-year follow-up were tested with a paired 
samples t-test. In samples of our size this t-test is valid independent of the distribution of the data42. In order to 
improve on comparability, effect sizes were given as Cohen’s d. Effect sizes of 0.20 were considered as small, 0.50 
as moderate, and 0.80 as large43. Cross-sectional correlations between AS and anxiety severity at baseline and at 
2-year follow-up were calculated with Spearman’s rho. The stability of AS was tested with a Spearman’s correlation 
test. We classified correlations (r) as very weak if between 0.00–0.29, weak between 0.30–0.49, moderate between 
0.50–0.69, strong between 0.70–0.89, and very strong from 0.90 onwards44.
Prior to conducting the longitudinal analyses, multicollinearity for all variables was checked by calculating 
Spearman correlations and the variance inflation factors (VIF). A Spearman correlation above 0.80 and VIF val-
ues above 10 were considered as indicative of severe collinearity45,46. The highest Spearman correlation was 0.74. 
The VIF values of all variables were between 1.00 and 1.62. This indicates that all variables could be maintained in 
the study without multicollinearity affecting the outcomes too much.
When testing the longitudinal associated changes in AS and changes in anxiety severity over the two-years 
follow-up time we had to take into account the fact that the data of the two measurements are correlated. The gen-
eralized estimating equations (GEE) analysis is a regression analysis technique that takes account of the depend-
encies between data and adjusts for the within-subject correlations, which makes this technique very suitable 
for the analysis of longitudinal data. Furthermore, GEE can handle data with a non-normal distribution47 In the 
GEE analyses, AS (independent variable) and anxiety severity (dependent variable) were analyzed simultaneously 
at both measurement waves to determine the development of AS and anxiety severity over time. A regression 
coefficient was estimated which reflects the longitudinal association between the change in AS and the change in 
anxiety severity. Missing data were not imputed as GEE can take these adequately into account48,49.
First, a univariable GEE analysis was conducted with AS and anxiety severity. Second, a multivariable GEE 
analysis was conducted in which the covariates were entered to the model. Gender, age, years of education, and 
duration of anxiety symptoms at baseline were treated as time-independent factors, whereas psychological treat-
ment and frequent use of antidepressants were analyzed as time-dependent factors.
A p-value < 0.05 was considered to indicate statistical significance. The statistical analyses were performed in 
IBM SPSS version 23.0 (IBM SPSS statistics for windows, version 23.0., 2013)50.
Results
Descriptives. Characteristics of the study sample at baseline are summarized in Table 1. Of the whole sample, 
652 participants (31.77%) reported no current or lifetime disorder, and 1400 participants (68.23%) had an anxiety 
and/or depressive disorder diagnosis. Almost half of the participants (46.20%) received psychological treatment 
and 22.12% used antidepressants. It should be noted that 494 participants (75.77%) in the group without current 
or lifetime DSM diagnosis, mentioned anxiety symptoms. In addition, 51 participants without current of lifetime 
diagnosis (7.82%) reported some kind of psychological treatment and 5 participants (0.77%) used antidepres-
sants. Additional information about the baseline characteristics of the separate diagnosis groups and the group 
without a current or lifetime diagnosis is given in the Supplementary materials Table S1.
AS decreased from baseline to two-year follow-up (30.02 ± 9.95 vs. 27.66 ± 8.51; t(1448) = 12.75, p < 0.001) 
with a moderate effect size (Cohen’s d = 0.34). Next, to facilitate the interpretation of the planned longitudinal 
association between change in AS and change in anxiety severity, the change of anxiety severity over two-year 
follow-up was also tested. Anxiety severity decreased (12.95 ± 10.98 vs. 9.60 ± 9.21; t(1693) = 17.34, p < 0.001). 
The effect size was moderate (Cohen’s d = 0.43).
Cross-sectional and temporal correlations. Correlations between all study variables are provided in 
Supplementary Table S2. AS and anxiety severity showed moderately positive cross-sectional associations at base-
line (r = 0.67, p < 0.001), and at follow-up (r = 0.58, p < 0.001). Change in AS over the two year interval showed 
very weak associations with all other variables (r = 0.06 to 0.25; p < 0.05 to p < 0.001). The test-retest correlations 
of AS (r = 0.72, p < 0.001) and anxiety severity (r = 0.74, p < 0.001) were large, indicating substantial stability.
Longitudinal associations. All longitudinal associations between the changes in AS and changes in anx-
iety severity are provided in Table 2. The univariable analysis showed that a decrease in AS was associated with 
a decrease in anxiety severity (p < 0.001). This result means that a change of one point of AS over the two-year 
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time period is associated with a change of 0.64 in anxiety severity. In the multivariable analysis, which included 
all covariates, the longitudinal association between the change in AS and change in anxiety severity remained 
statistically significant (p < 0.001), although the estimate for B decreased slightly.
Some studies suggested that specific AS subfactors accounted for associations between AS and anxiety or 
mood51,52, whereas all AS factors have been implicated in suicidal ideation14. Post-hoc we tested whether the 
association between AS and anxiety severity was primarily driven by physical or by social-cognitive factors, using 
the physical and social-cognitive AS subscales of the ASI instrument51. Repeating the analyses with these two 
subscales separately showed that the results were comparable to those described above for the full ASI scale (see 
Supplementary materials S3 and S4), which suggests that both factors play a role in the link with severity of anx-
iety symptoms.
Discussion
This study in this large and heterogeneous cohort of adult participants with and without a diagnosed anxiety and/
or depressive disorder, yielded two key observations. First, AS showed a strong two-year stability with a moderate 
decrease over time that was in the same range as the decrease in severity of anxiety symptoms over time. Second, 
the decrease in AS was positively associated with a decrease in severity of anxiety symptoms.
Baseline characteristics Mean (SD)/n (%)
Sociodemographics
   Age, in years 41.64 (13.10)
   Female gender, n (%) 1330 (64.81)
   Education in years 12.00 (3.27)
Diagnosis
   Anxiety disorder, n (%) 558 (27.19)
   Depressive disorder, n (%) 307 (14.96)
   Comorbid anxiety-depressive disorder, n (%) 535 (26.07)
   No current or lifetime diagnosis, n (%) 652 (31.77)
Anxiety symptoms
   Duration with anxiety symptoms (LCI), in number of months 24.73 (19.54)
   Anxiety Sensitivity (ASI) 30.20 (10.05)
   Severity of anxiety symptoms (BAI) 13.88 (11.52)
Treatment
   Receiving psychological treatment, last 6 months, n (%)* 948 (46.20)
   Current frequent** use of antidepressants, n (%)* 454 (22.12)
Table 1. Baseline characteristics for the study sample (N = 2052). Means (SD) are given unless stated otherwise. 
Note: BAI = Beck Anxiety Inventory; LCI = Life Chart Interview; *Combinations of treatments occur; 
**Frequent ≥ 50% of the days of a month (further details are provided in the method section).
Severity of anxiety symptoms
B 95% CI p
Univariable
AS 0.64 0.60; 0.68 <0.001
Multivariable
AS 0.52 0.48; 0.57 <0.001
Age 0.02 −0.02; 0.05 0.29
Female gender 0.43 −0.49; 1.35 0.36
Education in years −0.33 −0.46; −0.19 <0.001
Duration with anxiety symptoms (LCI), in number of months 0.06 0.04; 0.09 <0.001
Receiving psychological treatment, last 6 months −2.34 −3.10; −1.57 <0.001
Current frequent **use of antidepressants, n (%)* −1.69 −2.57; −0.81 <0.001
Table 2. Longitudinal associations between change in anxiety sensitivity (AS) and change in severity of 
anxiety symptoms (anxiety severity), analyzed with generalized estimating equations. Note: Univariable 
analyses: AS = independent factor; Multivariable analyses: AS = independent factor adjusted for the time-
independent covariates gender, age, years of education, and duration of anxiety symptoms at baseline and the 
time-dependent covariates psychological treatment and frequent use (i.e. ≥50% of the days of a month) of 
antidepressants. *Combinations of treatments occur; **Frequent ≥ 50% of the days of a month (further details 
are provided in the method section). Values in bold indicate statistical significance. Post-hoc analyses were 
performed on the physical and social-cognitive subscales of the ASI-instrument. Results are described in the 
text, and tables are shown in the Supplementary materials S3 and S4.
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We found a combination of high rank-order consistency and moderate decrease in mean-level AS scores. 
These statistics can be interpreted incorrectly. It may seem that AS scores of all participants would have decreased 
to the same extent, yet the significant mean-level change explained only a marginal part of the two-year test-retest 
stability of AS (i.e. d = 0.34 translates roughly to r = 0.17, thus about 3% explained variance (R2) in AS at 
follow-up), which cannot be considered of much importance to our interpretations of AS stability. Although 
AS proved to be a highly stable characteristic, the test-retest estimate also leaves room for potentially substantial 
changes in some individuals as well53. A combination of genetic factors, which are generally stable over time, and 
environmental factors, which can be time-specific, could be the cause of this result, as indicated by Zavos et al.18 
in a study AS in adolescent twins.
The comparable decreases in AS and severity of anxiety symptoms over the two-year interval, in combina-
tion with the positive association between these changes suggests that the two constructs are connected but not 
necessarily similar. There are important conceptual differences; whereas severity of anxiety symptoms refers to 
the extent to which actual symptoms are perceived, AS refers to a misinterpretation of these symptoms, namely 
the belief that anxiety symptoms are harmful and will have catastrophic consequences. This misinterpretation 
can potentially lead to more and more severe anxiety symptoms54. In the multivariate analyses, where potential 
confounding influences were taken into account, both psychological treatment and the use of antidepressants 
were associated with a change in severity of anxiety symptoms (Table 2). However, correlations indicated that 
psychological and pharmacological treatment were not associated with a decrease in AS (Supplementary mate-
rials). These findings underline that AS and severity of anxiety symptoms are two different constructs. In line 
with previous studies4,20,55, the results of our study support the conclusion that AS can be conceived as a more 
generic psychological construct directly related to severity of anxiety symptoms. It has been suggested that the 
link between AS and anxiety and mood are driven by the cognitive aspects of AS52,56, but our post-hoc analyses 
indicated that both physical and social-cognitive AS factors were implicated in changes in the severity of anxiety 
symptoms, in line with a recent meta-analyses that linked all AS factors to suicidal ideation14.
The longitudinal association between a change in AS and a change in severity of anxiety symptoms is interesting 
from a clinical perspective, as a core treatment intervention for individuals suffering from panic attacks is interoceptive 
exposure57. This approach targets AS by deliberately bringing on physical sensations that are harmless, yet feared. For 
example, an individual with a panic disorder might be instructed to undergo a hyperventilation provocation exercise in 
order to make his or her heart rate speed-up or feel dizzy, and therefore learn that these sensations are not dangerous. 
It would be worthwhile to examine whether intervening on AS is beneficial not only for individuals suffering from 
panic attacks, but for all individuals who suffer from anxiety symptoms. An indication that a treatment focused on 
AS can be successful is reported by Watt and Stewart58, and by Schmidt et al.22. The first study showed that a treatment 
program aiming at reducing AS can also reduce anxiety and depressive symptoms, and the latter showed that a com-
puterized treatment can reduce elevated AS levels in patients with severe pathology and suicidal ideation. The findings 
of these studies are also important because a recent meta-analysis showed that AS was associated with suicidal thoughts 
and behaviors14. In sum, treatment aiming at reducing an individual’s AS level may have an additional advantage as it 
diminishes the risk of future development of anxiety psychopathology and anxiety disorders and even of other Axis I 
disorders59.
The results of this study expand the literature on the stability of AS over time in adults. The second aim was to 
analyze the associations between changes in AS and changes in severity of anxiety symptoms. Strengths of this study 
include its large heterogeneous sample size, the broad range of repeated assessments of psychopathology, and the 
fact that participants were recruited from various settings and with different stages of disorder. At the same time, 
the results are subject to some limitations. First, since AS levels were previously found to differ between different 
anxiety disorder diagnoses55, the association between changes in AS and severity of anxiety symptoms may differ 
between the different anxiety disorder groups. In analogy, this might also apply to the different depressive disorders. 
However, given the high comorbidity between different anxiety disorders60, the low temporal stability of anxiety 
disorder diagnoses61,62, and the high comorbidity rates between anxiety and depressive disorders63,64, we believe that 
in our longitudinal model such analyses would not provide additional information to the current study. Second, 
assessment of AS and severity of anxiety symptoms relies on self-report measures. Although these instruments were 
proven to be reliable and valid, they might be subject to social desirability and recall bias65. Third, it should be noted 
that our finding that AS is associated with severity of anxiety symptoms does not infer causality, which requires 
studies of individual level processes and interventions66. Fourth, AS was tested with the original ASI32. The more 
recently developed ASI-3 appears to have better psychometric properties67, but within NESDA, the original ASI has 
been used to enable longitudinal analysis. Fifth, it would be interesting to study processes related to AS with more 
frequent assessments, as this higher time resolution may help further unravel the dynamics of stability and change 
in AS. Future studies of individual differences in AS stability and change processes are needed66, next to normative 
change68. However, these kinds of analyses are beyond the scope of this study. Finally, our analyses do not contribute 
much to the debate about the overlap between AS and trait-anxiety (see introduction), although the stabilities we 
observed for AS seem somewhat lower69. Future studies may examine how the stability of AS compares to the stabil-
ity of trait anxiety and other related psychological constructs such as neuroticism, rumination, and worry, as well as 
their overlap and incremental value.
Conclusion
The stability of AS is strong and comparable to related psychological trait constructs. Decreases in AS are associated 
with decreases in severity of anxiety symptoms. This result may imply that intervening on AS may be beneficial for 
all individuals who are suffering from anxiety symptoms. Future research is recommended to establish whether a 
treatment focused at reducing AS is of added value for reducing current anxiety symptoms as well as long-term relapse 
prevention effects.
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Data Availability
The datasets analyzed during the current study are available upon reasonable request from NESDA, Amsterdam: 
nesda@ggzingeest.nl.
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